Dr. Harmon is a Senior Research Fellow in Bioproduct Research and Development at Eli Lilly and Company. Following receipt of his B.S. degree in Chemistry from Rose-Hulman Institute of Technology, Dr. Harmon completed his Ph.D. studies in Analytical Chemistry under the direction of Professor Fred Regnier at Purdue University in 1994. He then completed a two-year position as a post-doctoral research associate in the laboratory of Professor Daniel I.C. Wang in the Biotechnology Process Engineering Center at Massachusetts Institute of Technology developing rapid mass spectrometry-based methods for glycosylation analysis of recombinant glycoproteins. He joined Lilly after working in the vaccine division of Merck Research Laboratories from 1996 to 1999. At Lilly, Dr. Harmon has been played a leading role in establishing strategies for comparability and Quality by Design, and he has provided technical leadership for several CMC development teams, including bamlanivimab.